As the US pricing situation continues to bite, industry veteran and newly-appointed Hikma chief executive officer Siggi Olafsson is confident the company’s superior balance sheet and diversified business operation, spread across three regions, will provide a competitive advantage. Dean Rudge reports.
With 2018 marking 40 years since Hikma Pharmaceuticals’ inception as a small company based in Jordan mainly supplying branded generics, the firm felt the time was ripe to unveil a new global brand platform, which includes a fresh logo and visual identity.
The “most notable change to the Hikma brand since the company’s founding in 1978”, Hikma’s new brand platform – “Better...
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
